Search

everythinglearnresearchcommunity

for

Search:↓

Oral minoxidil is considered more convenient and effective than topical or sublingual forms, with users reporting positive results and minimal side effects. Some users experience side effects with oral minoxidil and opt for sublingual or topical methods instead.

Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

User shared 3-month progress using Minoxidil 5% and Finasteride 0.1%, switching brands after the first month. Replies suggest the progress is good, with concerns about patches and shedding.

The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.

A woman with AGA is using spironolactone, dutasteride, finasteride, oral minoxidil, bicalutamide, and anti-androgenic birth control but still experiences worsening hair loss. Steroid shots temporarily stop her hair shedding, leading her to question her biopsy results.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

The conversation discusses experiences with topical dutasteride for hair loss, comparing formulations from FUEClinic, MinoxidilMax, and Strut. Users share their results and side effects, with some preferring topical over oral treatments to minimize systemic absorption.

The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.

Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

A user shared their 8-month progress using oral dutasteride and 2.5 mg oral minoxidil daily, reporting improved hair density with minimal side effects, except for a slightly decreased libido. They did not use any supplements but occasionally used a derma stamp.

A user shared their 3-month progress using oral minoxidil, finasteride, and topical minoxidil for hair loss. Another user commented on the significant improvement, hoping for similar results.

The user mixes their own RU58841 solution and found that increasing the ethanol content improved absorption and reduced scalp itching. A study on minoxidil showed that penetration increased with higher ethanol concentrations, reaching maximum penetration at 90% ethanol.

Microneedling may enhance the effectiveness of liposomal minoxidil for hair loss. The user is also using tretinoin.

The user experienced hair growth using 5% topical Minoxidil foam twice daily from October 2024 to February 2025, without using finasteride due to family history of side effects. The user is considering other treatments like topical finasteride and received positive feedback on their progress.

Minoxidil was applied to a single miniaturized hair follicle over four months, resulting in less miniaturization but not yet terminal growth. The user used a 5% minoxidil solution, specifically the Regaine brand, and observed changes using a handheld WiFi microscope.

A user is considering combining oral and topical dutasteride to lower scalp DHT more effectively and is seeking advice on this approach. They are thinking about doing a patch test on their mid scalp.

A user shared progress pictures after 7 months of 5% topical Minoxidil and 3 months of 1000mg daily Pumpkin Seed oil. Replies suggest adding finasteride for better results.

The conversation is about managing scalp irritation caused by minoxidil use. Suggestions include switching to foam, using fluocinonide topical solution, trying lipogaine for sensitive skin, and considering low-dose oral minoxidil.

Switching from liquid to foam Minoxidil to avoid scalp irritation, with a method to melt the foam for easier application. Users discuss alternatives and personal experiences with Minoxidil, including issues with propylene glycol and different application methods.

Minoxidil can cause face bloating, especially when combined with microneedling, as it may increase systemic absorption. Alternatives like Stemoxidine or Aminexil are considered, and some users find relief by adjusting application timing or switching brands.

The user is using a combination of oral Dutasteride and Minoxidil, and a topical formula with Finasteride, Minoxidil, and Hydrocortisone, along with rosemary oil, coconut oil, ginseng, and a derma roller. They are also using LLLT therapy and are questioning the timing of the laser cap session in relation to the topical application.

The conversation is about using a topical solution of latanoprost and minoxidil for hair loss, with concerns about side effects due to a history of gynecomastia. The user is considering this treatment instead of finasteride and is seeking experiences from others.

The user has tried various hair loss treatments including topical minoxidil, oral finasteride, oral dutasteride, oral minoxidil, and exosome therapy, but none have been effective. They suspect trichodynia might be preventing these treatments from working.

A user reports persistent sexual side effects three months after stopping finasteride, despite a healthy lifestyle and supplements. They express concern over the lack of libido and infrequent erections.

Veradermics is working on FDA approval for extended-release oral Minoxidil. Approval is expected around 2027.

OP is considering Bicalutamide for female AGA and TE but is concerned about its side effects and effectiveness compared to Finasteride. OP is also using Minoxidil and Spironolactone but is experiencing significant shedding and is unsure if it's androgen-driven or due to Minoxidil changes.

The user has been using 0.25% topical finasteride for eight months with slight improvement and is considering switching to oral finasteride for convenience and potentially better results. Increasing the topical concentration to 0.33% or 0.5% is also an option, but oral finasteride may have more systemic side effects.

A user discusses a topical treatment combining Minoxidil, Betamethasone Valerate, Canrenone, Finasteride, and Dutasteride for hair loss. The treatment is RX-only and provided by a dermatologist.